Amgen (AMGN) vs Neurocrine Biosciences (NBIX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Amgen (AMGN) has outperformed Neurocrine Biosciences (NBIX) over the past year, gaining 39.8% versus a gain of 4.7%. Over five years, AMGN leads with a +98.7% price change compared with +37.2% for NBIX. Amgen is the larger company by market cap ($223.32 billion vs $14.58 billion), about 15.3 times the size, while Neurocrine Biosciences is growing revenue faster (+21.4% vs +10.0%).
On valuation, Neurocrine Biosciences trades at a lower forward P/E (12.1x vs 16.9x for Amgen). Amgen pays a dividend yielding 2.37%, while Neurocrine Biosciences does not currently pay one. Amgen converts more of its revenue into profit, with a net margin of 21.0% versus 16.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMGN | NBIX |
|---|---|---|
| Share price | $413.08 | $143.47 |
| Market cap | $223.32B | $14.58B |
| 1-day change | +2.60% | -1.40% |
| YTD return | +26.20% | +1.16% |
| 1-year return | +39.77% | +4.72% |
| 5-year return | +98.75% | +37.24% |
| P/E ratio (TTM) | 25.00 | 21.32 |
| Forward P/E | 16.88 | 12.08 |
| EPS (TTM) | $16.52 | $6.73 |
| Dividend yield | 2.37% | 0.00% |
| Annual dividend | $9.80 | $0.00 |
| Revenue (latest FY) | $36.75B | $2.86B |
| Revenue growth (YoY) | +9.95% | +21.45% |
| Net income (latest FY) | $7.71B | $478.60M |
| Gross margin | 67.25% | 98.18% |
| Operating margin | 24.71% | 21.64% |
| Net margin | 20.98% | 16.73% |
| 52-week high | $447.03 | $186.12 |
| 52-week low | $288.00 | $122.14 |
| Distance from 52-week high | -7.59% | -22.92% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | -5.23% | +44.48% |
| Average volume | 2.72M | 1.30M |
| Shares outstanding | 540.63M | 101.65M |
| Employees | 31,500 | 2,500 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Amgen is about 15.3 times larger than Neurocrine Biosciences by market value ($223.32B vs $14.58B).
- AMGN has outperformed NBIX by 35.0 percentage points over the past year.
- Amgen offers a meaningfully higher dividend yield (2.37% vs 0.00%).
- Neurocrine Biosciences grew revenue faster in its latest fiscal year (+21.45% vs +9.95%).
- The two companies sit in different sectors: Amgen in Health Care and Neurocrine Biosciences in Healthcare.
About Amgen
AMGN stock →Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 31,500 employees
About Neurocrine Biosciences
NBIX stock →Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
Healthcare · Drug Manufacturers - Specialty & Generic · 2,500 employees
AMGN vs NBIX FAQ
Which is bigger, Amgen or Neurocrine Biosciences?
Amgen (AMGN) is larger, with a market capitalization of $223.32B compared with $14.58B for Neurocrine Biosciences (NBIX).
Which stock has performed better over the past year, AMGN or NBIX?
AMGN returned +39.77% over the past 12 months, compared with +4.72% for NBIX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, AMGN or NBIX?
NBIX has the lower trailing P/E at 21.3, versus 25.0 for AMGN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Amgen or Neurocrine Biosciences?
Amgen pays a dividend yielding 2.37%, while Neurocrine Biosciences does not currently pay a regular dividend.
Are Amgen and Neurocrine Biosciences in the same industry?
No. Amgen is in the Health Care sector, while Neurocrine Biosciences is in Healthcare.